SCHEMBL16899220

SCHEMBL16899220

CC(C)(C)[Si](C)(C)OCC1CCN(c2cc3[nH]ncc3cc2[N+](=O)[O-])CC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ MAPT P10636 8/20 0.35
▸ ALDH1A1 P00352 4/20 0.35
▸ LMNA P02545 2/20 0.35
▸ HTT P42858 2/20 0.35
▸ GAA P10253 2/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ TP53 P04637 3/20 0.34
▸ POLB P06746 3/20 0.34
▸ TRPA1 O75762 1/20 0.34
▸ TRPM8 Q7Z2W7 1/20 0.34
▸ TRPV1 Q8NER1 1/20 0.34
▸ GPR174 Q9BXC1 2/20 0.33
▸ NOS1 P29475 2/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ MAOB P27338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16899214 0.86 MEN1 (0.39) SMN1; SMN2MEN1KMT2AMAPTALDH1A1
SCHEMBL18889899 0.82 MEN1 (0.39) SMN1; SMN2MEN1KMT2AMAPTALDH1A1
SCHEMBL18207804 0.82 SMN1; SMN2 (0.43) SMN1; SMN2MEN1KMT2AMAPTALDH1A1
SCHEMBL16899042 0.81 SMN1; SMN2 (0.42) SMN1; SMN2MEN1KMT2AMAPTALDH1A1
SCHEMBL16899034 0.80 ALDH1A1 (0.38) SMN1; SMN2MEN1KMT2AMAPTALDH1A1
SCHEMBL16898863 0.80 SMN1; SMN2 (0.43) SMN1; SMN2MEN1KMT2AMAPTALDH1A1
SCHEMBL17373854 0.80 SMN1; SMN2 (0.39) SMN1; SMN2MEN1KMT2AMAPTALDH1A1
SCHEMBL16898952 0.79 LMNA (0.36) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL16898951 0.79 LMNA (0.36) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL31324405 0.79 MEN1 (0.41) SMN1; SMN2MEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3092226-B1 INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS AURIGENE DISCOVERY TECH LTD (IN) 2019-03-13 — — EP disclosed
US-10160753-B2 Indazole compounds as IRAK4 inhibitors AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2018-12-25 — — US disclosed
EP-3092226-A1 INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS Aurigene Discovery Technologies Limited (IN) 2016-11-16 — — EP disclosed
US-20160326151-A1 Indazole Compounds as IRAK4 Inhibitors AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2016-11-10 — — US disclosed
WO-2015104662-A1 INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2015-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10160753-B2 Indazole compounds as IRAK4 inhibitors IRAK4, IRAK3, IRAK1 SMN1; SMN2 1117/4885MEN1 2151/4885KMT2A 341/4885
US-20160326151-A1 Indazole Compounds as IRAK4 Inhibitors IRAK4, IRAK3, IRAK1 SMN1; SMN2 1117/4885MEN1 2151/4885KMT2A 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback